Literature DB >> 23602007

The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.

Jacqueline K Flynn1, Geza Paukovics, Miranda S Moore, Anne Ellett, Lachlan R Gray, Renee Duncan, Hamid Salimi, Becky Jubb, Mike Westby, Damian F J Purcell, Sharon R Lewin, Benhur Lee, Melissa J Churchill, Paul R Gorry, Michael Roche.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) resistance to CCR5 antagonists, including maraviroc (MVC), results from alterations in the HIV-1 envelope glycoproteins (Env) enabling recognition of antagonist-bound CCR5. Here, we characterized tropism alterations for CD4+ T-cell subsets and macrophages by Envs from two subjects who developed MVC resistance in vivo, which displayed either relatively efficient or inefficient recognition of MVC-bound CCR5. We show that MVC-resistant Env with efficient recognition of drug-bound CCR5 displays a tropism shift for CD4+ T-cell subsets associated with increased infection of central memory T-cells and reduced infection of effector memory and transitional memory T-cells, and no change in macrophage infectivity. In contrast, MVC-resistant Env with inefficient recognition of drug-bound CCR5 displays no change in tropism for CD4+ T-cell subsets, but exhibits a significant reduction in macrophage infectivity. The pattern of HIV-1 tropism alterations for susceptible cells may therefore be variable in subjects with MVC resistance.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23602007     DOI: 10.1016/j.virol.2013.03.026

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4+ T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained.

Authors:  Michael Roche; Carolin Tumpach; Jori Symons; Matthew Gartner; Jenny L Anderson; Gabriela Khoury; Kieran Cashin; Paul U Cameron; Melissa J Churchill; Steven G Deeks; Paul R Gorry; Sharon R Lewin
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

Review 2.  HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies.

Authors:  Paul R Gorry; Nicholas Francella; Sharon R Lewin; Ronald G Collman
Journal:  J Leukoc Biol       Date:  2013-10-24       Impact factor: 4.962

3.  A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.

Authors:  Javier Garcia-Perez; Isabelle Staropoli; Stéphane Azoulay; Jean-Thomas Heinrich; Almudena Cascajero; Philippe Colin; Hugues Lortat-Jacob; Fernando Arenzana-Seisdedos; Jose Alcami; Esther Kellenberger; Bernard Lagane
Journal:  Retrovirology       Date:  2015-06-18       Impact factor: 4.602

Review 4.  Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapies.

Authors:  Jacqueline K Flynn; Paul R Gorry
Journal:  Clin Transl Immunology       Date:  2014-07-18

5.  Differences in coreceptor specificity contribute to alternative tropism of HIV-1 subtype C for CD4(+) T-cell subsets, including stem cell memory T-cells.

Authors:  Kieran Cashin; Geza Paukovics; Martin R Jakobsen; Lars Østergaard; Melissa J Churchill; Paul R Gorry; Jacqueline K Flynn
Journal:  Retrovirology       Date:  2014-11-12       Impact factor: 4.602

6.  Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5.

Authors:  Christian Berg; Katja Spiess; Hans R Lüttichau; Mette M Rosenkilde
Journal:  Pharmacol Res Perspect       Date:  2016-10-18

7.  Modular Lentiviral Vectors for Highly Efficient Transgene Expression in Resting Immune Cells.

Authors:  Christina Fichter; Anupriya Aggarwal; Andrew Kam Ho Wong; Samantha McAllery; Vennila Mathivanan; Bailey Hao; Hugh MacRae; Melissa J Churchill; Paul R Gorry; Michael Roche; Lachlan R Gray; Stuart Turville
Journal:  Viruses       Date:  2021-06-18       Impact factor: 5.048

8.  A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.

Authors:  Michael Roche; Hamid Salimi; Renee Duncan; Brendan L Wilkinson; Kelechi Chikere; Miranda S Moore; Nicholas E Webb; Helena Zappi; Jasminka Sterjovski; Jacqueline K Flynn; Anne Ellett; Lachlan R Gray; Benhur Lee; Becky Jubb; Mike Westby; Paul A Ramsland; Sharon R Lewin; Richard J Payne; Melissa J Churchill; Paul R Gorry
Journal:  Retrovirology       Date:  2013-04-20       Impact factor: 4.602

9.  Quantifying susceptibility of CD4+ stem memory T-cells to infection by laboratory adapted and clinical HIV-1 strains.

Authors:  Jacqueline K Flynn; Geza Paukovics; Kieran Cashin; Katharina Borm; Anne Ellett; Michael Roche; Martin R Jakobsen; Melissa J Churchill; Paul R Gorry
Journal:  Viruses       Date:  2014-02-10       Impact factor: 5.048

10.  Decreased plasticity of coreceptor use by CD4-independent SIV Envs that emerge in vivo.

Authors:  Nicholas Francella; Sarah T C Elliott; Yanjie Yi; Sarah E Gwyn; Alexandra M Ortiz; Bing Li; Guido Silvestri; Mirko Paiardini; Cynthia A Derdeyn; Ronald G Collman
Journal:  Retrovirology       Date:  2013-11-12       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.